With over 4,000 manufacturing units, Gujarat flag bearer of India’s pharma industry: State govt

Gujarat has been the flag bearer of India‘s pharma industry and a hub for pharmaceutical manufacturing and exports for years, the state government has said as it gears up to host the Vibrant Gujarat Global Investor Summit. Gujarat provides employment to about 50,000 persons in over 4,000 manufacturing units producing allopathic, homoeopathic, ayurvedic and cosmetic drugs, according to a release by the state government.

As per official numbers, the state accounts for 53 per cent of India’s medical devices manufacturing and 78 per cent of the country’s cardiac stents manufacturing. About 40 per cent of the nation’s contract research organisations are based in Gujarat.

Ahead of the upcoming Vibrant Gujarat Global Investor Summit, Chief Minister Bhupendra Patel had earlier sought to highlight the state’s dominant role in the pharma sector. “Gujarat contributes 30 per cent of India’s pharmaceutical production and 28 per cent of total pharma export,” Patel had said.

The 10th edition of the Vibrant Gujarat event, which aims to pitch the state as the most favourable investment destination, will be held in January next year in Gandhinagar.

With over 700 pharma manufacturing licenses issued from 2020 to 2022, experts believe Gujarat’s share in the global pharmaceutical vertical is bound to skyrocket.

While 130 Gujarat registered pharma companies are United States Food and Drug Administration (USFDA) approved, 753 units are WHO Good Manufacturing Practices (GMP) approved.

“This vibrant Gujarat has been started by Narendra Modi. Since then, we have seen that everything is vibrant and huge investments are being made (in pharma sector). We are all connected to vibrant Gujarat, and our business has grown due to it,” said Sharad Patel, chairman of Sotac Pharmaceutical Limited.

Gujarat’s pharmaceutical sector is also noteworthy for its innovation and has expanded its business horizons to include the production of generics, research and development (R&D), contract research and manufacturing organisations (CRAMS), bulk drug productions, and new chemical entities (NCE), according to the state government.

Related Posts

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

The Central Drugs Standard Control Organisation (CDSCO) found one spurious and 220 not of standard quality (NSQ) drug samples from a batch tested randomly as part of the August drug…

FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

The action follows the department’s investigation into a large-scale unlicenced drug repacking and relabelling racket uncovered at a farmhouse in Bengaluru South district’s Bidadi on August 18. The Karnataka Food…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance

FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

FSDA cancels 16 pharmacy licences, suspends 8, including Pfizer depot

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

WHO launches new primary health care course to strengthen health systems globally

WHO launches new primary health care course to strengthen health systems globally

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman